Payment overview · 2025
General Payments
$495.21
23 reported records · 13 companies
Healthcare provider profile · identity verified
Amy Fowler, D.O
Allopathic & Osteopathic Physicians|Internal Medicine · HAZARD, KY · NPI 1801051891
Verified facts
What the public records show
CMS Open Payments records show Amy Fowler, D.O received $495.21 in general payments during 2025 across 23 reported records.
Madrigal Pharmaceuticals accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Leqvio, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Leqvio by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $149.86 | 30.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.28 | 12.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.34 | 11.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.54 | 10.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.02 | 7.3% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21.57 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.54 | 4.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.35 | 4.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.43 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.03 | 3.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.66 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.13 | 3.1% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.21 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $149.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.28 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.34 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.54 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 213 | exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 201 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
213 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
133 | 36 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
213 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
201 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1069 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 932 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 742 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 551 | 109 |
| Famotidine | Famotidine | 428 | 94 |
| Furosemide | Furosemide | 356 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 353 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 348 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 66 |
| Omeprazole | Omeprazole | 328 | 64 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 321 | 82 |
| Lisinopril | Lisinopril | 311 | 72 |
| Meloxicam | Meloxicam | 310 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 305 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 71 |
| Potassium Chloride | Potassium Chloride | 287 | 61 |
| Amitriptyline Hcl | Amitriptyline Hcl | 277 | 51 |
| Ozempic | Semaglutide | 270 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 261 | 53 |
| Montelukast Sodium | Montelukast Sodium | 251 | 55 |
| Farxiga | Dapagliflozin Propanediol | 246 | 45 |
| Trazodone Hcl | Trazodone Hcl | 240 | 48 |
| Ondansetron Hcl | Ondansetron Hcl | 234 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 61 |
| Losartan Potassium | Losartan Potassium | 214 | 45 |
| Jardiance | Empagliflozin | 213 | 45 |
| Mounjaro | Tirzepatide | 201 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 197 | 66 |
| Metformin Hcl | Metformin Hcl | 193 | 44 |
| Eliquis | Apixaban | 186 | 41 |
| Buspirone Hcl | Buspirone Hcl | 180 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 172 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 33 |
| Glipizide | Glipizide | 164 | 35 |
| Celecoxib | Celecoxib | 163 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 36 |
| Tramadol Hcl | Tramadol Hcl | 155 | 34 |
| Alprazolam | Alprazolam | 153 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 150 | 30 |
| Simvastatin | Simvastatin | 142 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 28 |
| Nifedipine Er | Nifedipine | 133 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 32 |
| Clonazepam | Clonazepam | 126 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 124 | 29 |
| Carvedilol | Carvedilol | 118 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 21 |
| Sertraline Hcl | Sertraline Hcl | 113 | 30 |
| Allopurinol | Allopurinol | 108 | 22 |
| Methylprednisolone | Methylprednisolone | 107 | 82 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 104 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 22 |
| Ezetimibe | Ezetimibe | 98 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 24 |
| Aripiprazole | Aripiprazole | 95 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 20 |
| Ibuprofen | Ibuprofen | 88 | 22 |
| Baclofen | Baclofen | 87 | 22 |
| Glyburide | Glyburide | 87 | 16 |
| Pregabalin | Pregabalin | 87 | 12 |
| Prednisone | Prednisone | 85 | 36 |
| Promethazine Hcl | Promethazine Hcl | 84 | 14 |
| Ondansetron Odt | Ondansetron | 81 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 18 |
| Donepezil Hcl | Donepezil Hcl | 77 | 14 |
| Fluconazole | Fluconazole | 76 | 40 |
| Methocarbamol | Methocarbamol | 75 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 72 | 11 |
| Atenolol | Atenolol | 71 | 16 |
| Levofloxacin | Levofloxacin | 69 | 53 |
| Spironolactone | Spironolactone | 68 | 13 |
| Sucralfate | Sucralfate | 67 | 18 |
| Bumetanide | Bumetanide | 66 | 17 |
| Trulicity | Dulaglutide | 66 | 14 |
| Levetiracetam | Levetiracetam | 65 | 13 |
| Nitroglycerin | Nitroglycerin | 63 | 25 |
| Nystatin | Nystatin | 63 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 60 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 14 |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 13 |
| Amoxicillin | Amoxicillin | 51 | 46 |
| Meclizine Hcl | Meclizine Hcl | 51 | 18 |
| Cilostazol | Cilostazol | 49 | suppressed |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 48 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Finasteride | Finasteride | 46 | 11 |
| Lansoprazole | Lansoprazole | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 15 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 33 |
| Nyamyc | Nystatin | 40 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 11 |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 29 |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 14 |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 21 |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Lactulose | Lactulose | 17 | 11 |
| Leqvio | Inclisiran Sodium | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Cephalexin | Cephalexin | 14 | 13 |
| Dofetilide | Dofetilide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.21 · 23 records | Madrigal Pharmaceuticals | ACTHAR, Bimzelx, CAPLYTA, FANAPT, HETLIOZ, JARDIANCE, LEQVIO, MOUNJARO, QULIPTA, REZDIFFRA, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error